Clinical trial BLU-667-2303
A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer
Cancers | |
---|---|
Organ | Lung |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | Blueprint Medicines Corporation |
EudraCT Identifier | 2019-002463-10 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04222972 |
Inclusion criteria | RET-fusion |
Last update |